GMED vs LLY
Globus Medical vs Eli Lilly and Company — AI-powered side-by-side comparison
GMED
Globus Medical
69
Buy
VS
LLY
Eli Lilly and Company
56
Buy
| Metric | GMED | LLY |
|---|
| AI Score |
69
|
56
|
| Price |
$83.93
|
$1,249.86
|
| P/E Ratio |
21.18×
|
41.81×
|
| ROE |
11.8%
|
77.8%
|
| Revenue Growth YoY |
—
|
—
|
| Gross Margin |
68.5%
|
84.0%
|
| Debt / Equity |
0.02×
|
1.62×
|
| Dividend Yield |
0.0%
|
0.5%
|
| RSI (14) |
46.8
|
59.0
|
| Beta |
0.954
|
0.506
|
| Expected Upside |
+0.2%
|
+0.1%
|
AI Committee View
Current Innellis committee reasoning for GMED versus LLY.
GMED leads by 13 points.
GMED scores 69/100 (Buy) versus LLY at 56/100 (Buy).
GMED Committee View
100% agreement
6 analysts
The primary driver is eps growing 50.9% yoy. The main limiting factor is sector concentration is already high (hhi 3063.01). The committee is constructive but not yet at full conviction.
Bull Case
- EPS growing 50.9% YoY — Growth
- 5 consecutive earnings beats -- consistent execution — Growth
- Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
Bear Case
- Price structure (LH_LL) contradicts the uptrend -- mixed signals — Technical
LLY Committee View
67% agreement
6 analysts
The committee is genuinely divided. Growth Analyst sees a compelling case — revenue growing 49.6% yoy -- genuine top-line momentum. Risk Analyst remains cautious — high leverage (debt-to-equity 1.60) amplifies downside in a stress scenario. This disagreement is itself the signal — the setup is not clean in either direction.
Bull Case
- ROE of 92.6% shows genuine earnings power backing the valuation — Value
- Revenue growing 49.6% YoY -- genuine top-line momentum — Growth
- EPS growing 94.6% YoY — Growth
Bear Case
- P/E of 43.2 is expensive by classic value standards — Value
- Price-to-book of 38.3x prices in significant intangible value — Value
- Debt-to-equity of 1.60 adds balance-sheet risk to the value case — Value